HRP20210144T1 - Kompozicije koje sadrže inhibitor lizin specifične demetilaze-1 koje imaju pirimidinski prsten i njihova primjena u liječenju raka - Google Patents
Kompozicije koje sadrže inhibitor lizin specifične demetilaze-1 koje imaju pirimidinski prsten i njihova primjena u liječenju raka Download PDFInfo
- Publication number
- HRP20210144T1 HRP20210144T1 HRP20210144TT HRP20210144T HRP20210144T1 HR P20210144 T1 HRP20210144 T1 HR P20210144T1 HR P20210144T T HRP20210144T T HR P20210144TT HR P20210144 T HRP20210144 T HR P20210144T HR P20210144 T1 HRP20210144 T1 HR P20210144T1
- Authority
- HR
- Croatia
- Prior art keywords
- theta
- pharmaceutical composition
- crystalline form
- cancer
- pharmaceutically acceptable
- Prior art date
Links
- 206010028980 Neoplasm Diseases 0.000 title claims 6
- 201000011510 cancer Diseases 0.000 title claims 5
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 title 1
- 239000004472 Lysine Substances 0.000 title 1
- 239000003112 inhibitor Substances 0.000 title 1
- 239000000203 mixture Substances 0.000 title 1
- 125000000714 pyrimidinyl group Chemical group 0.000 title 1
- 238000000634 powder X-ray diffraction Methods 0.000 claims 12
- 239000008194 pharmaceutical composition Substances 0.000 claims 10
- 150000003839 salts Chemical class 0.000 claims 7
- 238000001938 differential scanning calorimetry curve Methods 0.000 claims 3
- 229940125092 pulrodemstat Drugs 0.000 claims 3
- -1 4-[2-(4-amino-piperidin-1-yl)-5-(3-fluoro-4-methoxyphenyl)-1-methyl-6-oxo-1,6-dihydro-pyrimidin- 4-yl]-2-fluorobenzonitrile besylate salt Chemical class 0.000 claims 2
- 206010006187 Breast cancer Diseases 0.000 claims 2
- 208000026310 Breast neoplasm Diseases 0.000 claims 2
- 241000124008 Mammalia Species 0.000 claims 2
- 206010041067 Small cell lung cancer Diseases 0.000 claims 2
- 208000005017 glioblastoma Diseases 0.000 claims 2
- 208000002154 non-small cell lung carcinoma Diseases 0.000 claims 2
- 208000000587 small cell lung carcinoma Diseases 0.000 claims 2
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 claims 2
- 208000024893 Acute lymphoblastic leukemia Diseases 0.000 claims 1
- 208000031261 Acute myeloid leukaemia Diseases 0.000 claims 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical class CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 claims 1
- NBAIXBAUHIQQGF-UHFFFAOYSA-N NC1CCN(CC1)C=1N(C(C(=C(N1)C1=CC(=C(C#N)C=C1)F)C1=CC(=C(C=C1)OC)F)=O)C Chemical compound NC1CCN(CC1)C=1N(C(C(=C(N1)C1=CC(=C(C#N)C=C1)F)C1=CC(=C(C=C1)OC)F)=O)C NBAIXBAUHIQQGF-UHFFFAOYSA-N 0.000 claims 1
- 206010029260 Neuroblastoma Diseases 0.000 claims 1
- 206010060862 Prostate cancer Diseases 0.000 claims 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 1
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical class OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 claims 1
- SRSXLGNVWSONIS-UHFFFAOYSA-N benzenesulfonic acid Chemical compound OS(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-N 0.000 claims 1
- 229940092714 benzenesulfonic acid Drugs 0.000 claims 1
- 150000008107 benzenesulfonic acids Chemical class 0.000 claims 1
- 150000001558 benzoic acid derivatives Chemical class 0.000 claims 1
- 239000002775 capsule Substances 0.000 claims 1
- 239000013078 crystal Substances 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 239000004615 ingredient Substances 0.000 claims 1
- 208000032839 leukemia Diseases 0.000 claims 1
- 201000005202 lung cancer Diseases 0.000 claims 1
- 208000020816 lung neoplasm Diseases 0.000 claims 1
- 239000008184 oral solid dosage form Substances 0.000 claims 1
- 125000005489 p-toluenesulfonic acid group Chemical group 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 150000003016 phosphoric acids Chemical class 0.000 claims 1
- 239000006187 pill Substances 0.000 claims 1
- 239000003826 tablet Substances 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/32—One oxygen, sulfur or nitrogen atom
- C07D239/34—One oxygen atom
- C07D239/36—One oxygen atom as doubly bound oxygen atom or as unsubstituted hydroxy radical
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Claims (17)
1. Farmaceutski prihvatljiva sol 4-[2-(4-amino-piperidin-1-il)-5-(3-fluoro-4-metoksi-fenil)-1-metil-6-okso-1,6-dihidro-pirimidin-4-il]-2-fluorobenzonitrila, pri čemu je farmaceutski prihvatljiva sol u kristalnom obliku.
2. Farmaceutski prihvatljiva sol prema patentnom zahtjevu 1, pri čemu farmaceutski prihvatljiva sol je sol p-toluen sulfonske kiseline, sol sumporne kiseline, sol metansulfonske kiseline, sol benzensulfonske kiseline, sol fosforne kiseline, ili sol benzoeve kiseline.
3. Farmaceutski prihvatljiva sol prema patentnom zahtjevu 1, pri čemu farmaceutski prihvatljiva sol je sol benzensulfonske kiseline.
4. Kristalni oblik 1 4-[2-(4-amino-piperidin-1-il)-5-(3-fluoro-4-metoksifenil)-1-metil-6-okso-1,6-dihidro-pirimidin-4-il]-2-fluorobenzonitril bezilatne soli koji je okarakteriziran da ima:
(a) obrazac difrakcije X-zraka praha (XRPD) suštinski isti kao što je prikazano na SL. 1;
(b) obrazac difrakcije X-zraka praha (XRPD) sa karakterističnim pikovima na 4.9° 2-teta, 9.7° 2-teta, 13.4° 2-teta, 18.0° 2-teta, 18.5° 2-teta;
(c) DSC termogram sa endotermom koja ima početnu temperaturu na oko 317°C;
(d) DSC termogram suštinski sličan onome prikazanom na SL. 2;
ili
(e) njihovu kombinaciju.
5. Kristalni oblik prema patentnom zahtjevu 4, pri čemu kristalni oblik ima obrazac difrakcije X-zraka praha (XRPD) suštinski isti onome prikazanom na SL. 1.
6. Kristalni oblik prema patentnom zahtjevu 4, pri čemu kristalni oblik ima obrazac difrakcije X-zraka praha (XRPD) sa karakterističnim pikovima na karakterističnim pikovima na 4.9° 2-teta, 9.7° 2-teta, 13.4° 2-teta, 18.0° 2-teta, 18.5° 2-teta.
7. Kristalni oblik prema patentnom zahtjevu 4, pri čemu kristalni oblik ima suštinski isti obrazac difrakcije X-zraka praha (XRPD) posle čuvanja na 40°C i 75% RH tokom bar jednog tjedna, ili
pri čemu kristalni oblik ima suštinski isti obrazac difrakcije X-zraka praha (XRPD) poslije čuvanja na 25°C i 96% RH tokom bar jednog tjedna.
8. Kristalni oblik prema patentnom zahtjevu 4, pri čemu kristalni oblik ima DSC termogram sa endotermom koja ima početnu temperaturu na oko 317°C.
9. 4-[2-(4-amino-piperidin-1-il)-5-(3-fluoro-4-metoksi-fenil)-1-metil-6-okso-1,6-dihidro-pirimidin-4-il]-2-fluorobenzonitril bezilatna sol koja je u amorfnom obliku.
10. Farmaceutska kompozicija koja sadrži kristalni oblik prema bilo kojem od patentnih zahtjeva 1-8, ili koja sadrži amorfni oblik prema patentnom zahtjevu 9, i najmanje jedan dodatni sastojak odabran od farmaceutski prihvatljivih nosača, razblaživača i ekscipijenasa.
11. Farmaceutska kompozicija prema patentnom zahtjevu 10, pri čemu farmaceutska kompozicija je u obliku pogodnom za oralno administriranje sisaru.
12. Farmaceutska kompozicija prema patentnom zahtjevu 10, pri čemu je farmaceutska kompozicija u oralnom čvrstom doznom obliku, poželjno u obliku tablete, kapsule ili pilule.
13. Farmaceutska kompozicija prema bilo kojem od patentnih zahtjeva 10 do 12 za primjenu kao lijek.
14. Farmaceutska kompozicija prema bilo kojem od patentnih zahtjeva 10 do 13 za primjenu u liječenju raka kod sisavaca.
15. Farmaceutska kompozicija za primjenu prema patentnom zahtjevu 14, pri čemu je rak odabran iz grupe koja se sastoji od raka dojke, raka pluća, glioblastoma i leukemije.
16. Farmaceutska kompozicija za primjenu prema patentnom zahtjevu 14, pri čemu je rak rak prostate.
17. Farmaceutska kompozicija za primjenu prema patentnom zahtjevu 14, pri čemu je rak akutna mijeloidna leukemija (AML), akutna limfoblastna leukemija (ALL), sitnostanični rak pluća (SCLC), nesitnostanični rak pluća (NSCLC), neuroblastom, tumori malih okruglih plavih stanica, glioblastom, ili ER(-) rak dojke.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562251507P | 2015-11-05 | 2015-11-05 | |
| PCT/US2016/060694 WO2017079670A1 (en) | 2015-11-05 | 2016-11-04 | Compositions comprising an inhibitor of lysine specific demethylase-1 |
| EP16863111.7A EP3371152B1 (en) | 2015-11-05 | 2016-11-04 | Compositions comprising an inhibitor of lysine specific demethylase-1 having a pyrimidine ring and its use in the treatment of cancer |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| HRP20210144T1 true HRP20210144T1 (hr) | 2021-03-05 |
| HRP20210144T8 HRP20210144T8 (hr) | 2021-04-16 |
Family
ID=58662888
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20210144TT HRP20210144T8 (hr) | 2015-11-05 | 2021-01-27 | Kompozicije koje sadrže inhibitor lizin specifične demetilaze-1 koje imaju pirimidinski prsten i njihova primjena u liječenju raka |
Country Status (20)
| Country | Link |
|---|---|
| US (4) | US9828358B2 (hr) |
| EP (1) | EP3371152B1 (hr) |
| JP (1) | JP6995043B2 (hr) |
| CN (1) | CN108473442B (hr) |
| AR (1) | AR106612A1 (hr) |
| AU (1) | AU2016349707B2 (hr) |
| CA (1) | CA3004300C (hr) |
| CY (1) | CY1124078T1 (hr) |
| DK (1) | DK3371152T3 (hr) |
| ES (1) | ES2846951T3 (hr) |
| HR (1) | HRP20210144T8 (hr) |
| HU (1) | HUE053449T2 (hr) |
| LT (1) | LT3371152T (hr) |
| MX (2) | MX2020004894A (hr) |
| PL (1) | PL3371152T3 (hr) |
| PT (1) | PT3371152T (hr) |
| RS (1) | RS61404B1 (hr) |
| SI (1) | SI3371152T1 (hr) |
| TW (1) | TW201720808A (hr) |
| WO (1) | WO2017079670A1 (hr) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9255097B2 (en) | 2014-05-01 | 2016-02-09 | Quanticel Pharmaceuticals, Inc. | Inhibitors of lysine specific demethylase-1 |
| PL3371152T3 (pl) * | 2015-11-05 | 2021-06-28 | Celgene Quanticel Research, Inc. | Kompozycje zawierające inhibitor specyficznej dla lizyny demetylazy-1 mający pierścień pirymidynowy i jego zastosowanie w leczeniu nowotworów |
| US20190256930A1 (en) | 2016-11-03 | 2019-08-22 | Oryzon Genomics, S.A. | Biomarkers for determining responsiveness to lsd1 inhibitors |
| US20200069677A1 (en) | 2016-12-09 | 2020-03-05 | Constellation Pharmaceuticals, Inc. | Markers for personalized cancer treatment with lsd1 inhibitors |
| MX2020001323A (es) | 2017-08-03 | 2020-03-20 | Oryzon Genomics Sa | Metodos para tratar alteraciones del comportamiento. |
| AU2020242302A1 (en) | 2019-03-20 | 2021-09-16 | Oryzon Genomics, S.A. | Methods of treating borderline personality disorder |
| JP2022526755A (ja) | 2019-03-20 | 2022-05-26 | オリソン ヘノミクス，ソシエダ アノニマ | 化合物バフィデムスタット（ｖａｆｉｄｅｍｓｔａｔ）などｋｄｍ１ａ阻害剤を使用した注意欠陥多動性障害の処置方法 |
| EP3983016A4 (en) * | 2019-06-13 | 2023-06-07 | Celgene Corporation | METHODS OF TREATMENT OF CANCER BY TARGETING COLD TUMORS |
| JP2022537384A (ja) * | 2019-06-20 | 2022-08-25 | セルジーン コーポレーション | ベネトクラクス、ギルテリチニブ、ミドスタウリン、または白血病もしくは骨髄異形成症候群を治療するための他の化合物との組み合わせにおけるアザシチジン |
| CN114341366A (zh) | 2019-07-05 | 2022-04-12 | 奥莱松基因组股份有限公司 | 用于使用kdm1a抑制剂个体化治疗小细胞肺癌的生物标志物和方法 |
| CN116056707A (zh) * | 2020-06-05 | 2023-05-02 | 赛尔基因昆蒂赛尔研究公司 | 治疗前列腺癌的方法 |
| ES2919083R1 (es) * | 2020-06-29 | 2022-07-26 | Celgene Quanticel Res Inc | Métodos de tratamiento de cáncer de próstata |
| CA3231846A1 (en) | 2021-04-08 | 2022-10-13 | Tamara Maes | Combinations of lsd1 inhibitors for treating myeloid cancers |
| WO2023217758A1 (en) | 2022-05-09 | 2023-11-16 | Oryzon Genomics, S.A. | Methods of treating malignant peripheral nerve sheath tumor (mpnst) using lsd1 inhibitors |
| WO2023217784A1 (en) | 2022-05-09 | 2023-11-16 | Oryzon Genomics, S.A. | Methods of treating nf1-mutant tumors using lsd1 inhibitors |
| WO2024110649A1 (en) | 2022-11-24 | 2024-05-30 | Oryzon Genomics, S.A. | Combinations of lsd1 inhibitors and menin inhibitors for treating cancer |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5323907A (en) | 1992-06-23 | 1994-06-28 | Multi-Comp, Inc. | Child resistant package assembly for dispensing pharmaceutical medications |
| CA2513414A1 (en) * | 2002-04-10 | 2003-10-16 | Orchid Chemicals & Pharmaceuticals Limited | Pyrimidinedione derivatives useful for the treatment of inflammation and immunological diseases |
| AU2003216585A1 (en) * | 2002-04-10 | 2003-10-20 | Orchid Chemicals And Pharmaceuticals Limited | Pyrimidinedione derivatives useful for the treatment of inflammation and immunological diseases |
| US20070270446A1 (en) * | 2004-10-06 | 2007-11-22 | Smithkline Beecham Corporation | Reversed Pyrimidinone Compounds as Calcilytics |
| US20100137313A1 (en) * | 2008-10-03 | 2010-06-03 | Astrazeneca Ab | Heterocyclic derivatives and methods of use thereof |
| US10093646B2 (en) * | 2014-01-17 | 2018-10-09 | Novartis Ag | 1-pyridazin-/triazin-3-yl-piper(-azine)/idine/pyrolidine derivatives and compositions thereof for inhibiting the activity of SHP2 |
| US9255097B2 (en) * | 2014-05-01 | 2016-02-09 | Quanticel Pharmaceuticals, Inc. | Inhibitors of lysine specific demethylase-1 |
| PL3371152T3 (pl) * | 2015-11-05 | 2021-06-28 | Celgene Quanticel Research, Inc. | Kompozycje zawierające inhibitor specyficznej dla lizyny demetylazy-1 mający pierścień pirymidynowy i jego zastosowanie w leczeniu nowotworów |
-
2016
- 2016-11-04 PL PL16863111T patent/PL3371152T3/pl unknown
- 2016-11-04 RS RS20210094A patent/RS61404B1/sr unknown
- 2016-11-04 HU HUE16863111A patent/HUE053449T2/hu unknown
- 2016-11-04 CA CA3004300A patent/CA3004300C/en active Active
- 2016-11-04 MX MX2020004894A patent/MX2020004894A/es unknown
- 2016-11-04 WO PCT/US2016/060694 patent/WO2017079670A1/en active Application Filing
- 2016-11-04 PT PT168631117T patent/PT3371152T/pt unknown
- 2016-11-04 EP EP16863111.7A patent/EP3371152B1/en active Active
- 2016-11-04 ES ES16863111T patent/ES2846951T3/es active Active
- 2016-11-04 CN CN201680076854.5A patent/CN108473442B/zh active Active
- 2016-11-04 LT LTEP16863111.7T patent/LT3371152T/lt unknown
- 2016-11-04 US US15/344,426 patent/US9828358B2/en active Active
- 2016-11-04 MX MX2018005620A patent/MX2018005620A/es active IP Right Grant
- 2016-11-04 JP JP2018522953A patent/JP6995043B2/ja active Active
- 2016-11-04 AU AU2016349707A patent/AU2016349707B2/en active Active
- 2016-11-04 SI SI201631055T patent/SI3371152T1/sl unknown
- 2016-11-04 DK DK16863111.7T patent/DK3371152T3/da active
- 2016-11-07 TW TW105136105A patent/TW201720808A/zh unknown
- 2016-11-07 AR ARP160103391A patent/AR106612A1/es unknown
-
2017
- 2017-10-25 US US15/793,512 patent/US10047069B2/en active Active
-
2018
- 2018-07-10 US US16/032,002 patent/US10316016B2/en active Active
-
2019
- 2019-06-10 US US16/436,541 patent/US10703739B2/en active Active
-
2021
- 2021-01-27 HR HRP20210144TT patent/HRP20210144T8/hr unknown
- 2021-01-28 CY CY20211100072T patent/CY1124078T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20210144T1 (hr) | Kompozicije koje sadrže inhibitor lizin specifične demetilaze-1 koje imaju pirimidinski prsten i njihova primjena u liječenju raka | |
| PE20191543A1 (es) | Proceso para la preparacion de pirazolo[1,5-a]pirimidinas y sales de estas | |
| HRP20211244T1 (hr) | Farmaceutske kompozicije koje sadrže n-(3,5-dimetoksifenil)-n'-(1-metiletil)-n-[3-(1-metil-1h-pirazol-4-il)kvinoksalin-6-il]etan-1,2-diamin | |
| AR122395A2 (es) | Formas cristalinas de 5-cloro-n2-(2-isopropoxi-5-metil-4-piperidin-4-il-fenil)-n4-[2-(propan-2-sulfonil)-fenil]-pirimidin-2,4-diamina | |
| HRP20202073T1 (hr) | Derivati n-(fenilsulfonil)benzamida kao bcl-2 inhibitori | |
| CY1122046T1 (el) | Δικυκλικα ετεροκυκλικα παραγωγα ως αναστολεις βρομοτομεων | |
| UY37925A (es) | Formas cristalinas | |
| HRP20180133T1 (hr) | Čvrsti oblici 3-(5-amino-2-metil-4-okso-4h-kinazolin-3-il) piperidin-2,6-diona, te njihovi farmaceutski pripravci i upotreba | |
| BR112019007393A2 (pt) | derivados 6,7,8,9-tetra-hidro-3h-pirazolo[4,3-f]isoquinolina úteis no tratamento de câncer | |
| CY1119886T1 (el) | Μεθοδος βιομηχανικης κατασκευης μιας φαρμακευτικης συνθεσης στην μορφη δισκιων παρατεταμενης απελευθερωσης που περιεχουν πιρφενιδονη και χρηση αυτων στην υποστροφη χρονιας νεφρικης ανεπαρκειας, καψικης συσπασης μαστου και ηπατικης ινωσης σε ανθρωπους | |
| HRP20201343T1 (hr) | Kristalni oblici 5-kloro-n4-[-2-(dimetilfosforil)fenil]-n2-{2-metoksi-4-[4-(4-metilpiperazin-1-il)piperidin-1-il]pirimidin-2,4-diamina | |
| HRP20230271T1 (hr) | Kristalni oblik (s)-n-(5-((r)-2-(2,5-difluorofenil)-pirolidin-1-il)-pirazolo[1,5-a]pirimidin-3-il)-3-hidroksipirolidin-1-karboksamid hidrogen sulfata | |
| PH12015501517A1 (en) | Pyrimidone derivatives and their use in the treatment, amelioration or prevention of a viral disease | |
| JP2013237682A5 (hr) | ||
| HRP20191826T4 (hr) | Derivati n-piridinil acetamida kao inhibitori wnt signalnog puta | |
| MX2021013817A (es) | Nuevas formas cristalinas de n-(3-(2-(2-hidroxietoxi)-6-morfolinop iridin-4-il)-4-metilfenil)-2-(trifluorometil)isonicotinamida como inhibidores de raf para el tratamiento del cancer. | |
| CA2980478C (en) | Compositions and methods for inhibiting kinases | |
| JP2016533364A (ja) | 癌を処置する方法 | |
| AR100818A1 (es) | N-(cianometil)-4-(2-(4-morfolinofenilamino)pirimidin-4-il)benzamida | |
| PE20160550A1 (es) | Formulaciones de (s)-3-(4-((4-(morfolinometil)bencil)oxi)-1-oxoisoindolin-2-il)piperidin-2,6-diona | |
| HRP20201681T1 (hr) | Inhibitor aurora a kinaze | |
| HRP20201932T4 (hr) | Stimulatori / aktivatori topive gvanilat-ciklaze u kombinaciji s nep-inhibitorom i/ili angiotenzin aii-antagonistom i njihova uporaba | |
| JP2011500621A5 (hr) | ||
| US20090298843A1 (en) | Treatment of hematological malignancies with fts and a bcr-abl tyrosine kinase inhibitor | |
| HRP20230362T1 (hr) | Kompozicije koje sadrže triciklične heterorociklične spojeve |